Methods for treating bone tumors or other target tissues using radioisotopes mixed into a matrix material, most commonly bone cement.

Researchers at the University of California, Davis have developed advanced spectroscopy devices enabling real-time, cost-effective measurement of elemental composition in airborne particulate aerosols.

Researchers at the University of California, Davis have developed a refractory niobium-based complex concentrated alloy designed for exceptional strength and durability at ultrahigh temperatures with a significantly reduced material’s cost.

Researchers at the University of California, Davis have developed a method and device performing simultaneous flip and merge operations to improve logical operation performance in high-efficiency superconducting circuits.

Researchers at the University of California, Davis have developed a scalable, one-pot method to produce highly charged sulfated cellulose nanofibrils (SCNFs), which can be wet-spun into continuous, high-strength fibers and serve as effective polyanions in conductive polymer composites.

Transcription factors are critical regulators of gene expression, but they have long been considered "undruggable" due to their lack of deep, well-defined binding pockets and their high degree of intrinsic disorder. To overcome this, UC Berkeley researchers have developed a new class of covalent monovalent degraders that utilize chemoproteomic platforms to target and eliminate these proteins. Unlike traditional inhibitors that must compete with natural ligands for a binding site, these compounds form a permanent covalent bond with specific, often disordered cysteine residues on the target transcription factor. This interaction induces structural destabilization of the protein, triggering its recognition and subsequent destruction by the cell's ubiquitin-proteasome system. This platform has already successfully produced potent degraders for major oncogenic drivers such as $\beta$-catenin (CTNNB1), MYC, and the androgen receptor variant AR-V7.

Biological systems naturally synthesize precise, sequence-defined polymers—proteins and nucleic acids—that perform a staggering array of functions. However, the chemical diversity of these polymers is limited by the set of twenty canonical $\alpha$-amino acids. To overcome this limitation, researchers at UC Berkeley have pioneered a method for the programmed biosynthesis of heteropolymers with expanded backbones. By engineering orthogonal aminoacyl-tRNA synthetases (aaRS), such as variants of the pyrrolysyl-tRNA synthetase, the system can charge tRNAs with non-natural $\beta 2$-backbone substrates. These substrates are then incorporated by the ribosome into a growing polymer chain in vivo. This breakthrough allows for the creation of sequence-defined biomaterials that possess structural and chemical properties far beyond those of traditional proteins, including enhanced stability and novel folding patterns.

Addressing the global opioid crisis requires innovative pharmacological solutions that decouple effective pain relief from lethal side effects. Researchers at UC Berkeley have developed a suite of novel morphine framework derivatives engineered with a modified molecular skeleton to alter their bioactivity profiles significantly. Unlike traditional opioids, these derivatives are designed to interact with receptors in a way that provides potent analgesia while bypassing the pathways responsible for respiratory depression and addiction. Furthermore, certain variants within this framework exhibit antagonistic properties that could serve as a powerful alternative to naloxone for reversing opioid overdoses.